Logo image of GLUE

MONTE ROSA THERAPEUTICS INC (GLUE) Stock Fundamental Analysis

USA - NASDAQ:GLUE - US61225M1027 - Common Stock

10.56 USD
-0.55 (-4.95%)
Last: 10/16/2025, 1:11:18 PM
Fundamental Rating

5

Taking everything into account, GLUE scores 5 out of 10 in our fundamental rating. GLUE was compared to 536 industry peers in the Biotechnology industry. While GLUE has a great health rating, its profitability is only average at the moment. GLUE is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year GLUE was profitable.
GLUE had a positive operating cash flow in the past year.
GLUE had negative earnings in each of the past 5 years.
In the past 5 years GLUE reported 4 times negative operating cash flow.
GLUE Yearly Net Income VS EBIT VS OCF VS FCFGLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

GLUE has a better Return On Assets (6.72%) than 91.98% of its industry peers.
Looking at the Return On Equity, with a value of 9.02%, GLUE belongs to the top of the industry, outperforming 93.10% of the companies in the same industry.
GLUE has a better Return On Invested Capital (3.72%) than 91.60% of its industry peers.
Industry RankSector Rank
ROA 6.72%
ROE 9.02%
ROIC 3.72%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
GLUE Yearly ROA, ROE, ROICGLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With an excellent Profit Margin value of 13.58%, GLUE belongs to the best of the industry, outperforming 93.10% of the companies in the same industry.
GLUE has a Operating Margin of 8.40%. This is amongst the best in the industry. GLUE outperforms 91.60% of its industry peers.
Industry RankSector Rank
OM 8.4%
PM (TTM) 13.58%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLUE Yearly Profit, Operating, Gross MarginsGLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GLUE is destroying value.
GLUE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GLUE has been increased compared to 5 years ago.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLUE Yearly Shares OutstandingGLUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLUE Yearly Total Debt VS Total AssetsGLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 4.42 indicates that GLUE is not in any danger for bankruptcy at the moment.
The Altman-Z score of GLUE (4.42) is better than 72.95% of its industry peers.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.42
ROIC/WACC0.4
WACC9.36%
GLUE Yearly LT Debt VS Equity VS FCFGLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

GLUE has a Current Ratio of 7.16. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.16, GLUE is doing good in the industry, outperforming 69.78% of the companies in the same industry.
A Quick Ratio of 7.16 indicates that GLUE has no problem at all paying its short term obligations.
The Quick ratio of GLUE (7.16) is better than 70.34% of its industry peers.
Industry RankSector Rank
Current Ratio 7.16
Quick Ratio 7.16
GLUE Yearly Current Assets VS Current LiabilitesGLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 115.63% over the past year.
Looking at the last year, GLUE shows a very strong growth in Revenue. The Revenue has grown by 2990.57%.
EPS 1Y (TTM)115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
Revenue 1Y (TTM)2990.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%394.01%

3.2 Future

GLUE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.65% yearly.
GLUE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.64% yearly.
EPS Next Y80.7%
EPS Next 2Y-16.8%
EPS Next 3Y-7.56%
EPS Next 5Y-6.65%
Revenue Next Year413.34%
Revenue Next 2Y39.97%
Revenue Next 3Y36.05%
Revenue Next 5Y22.64%

3.3 Evolution

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

GLUE is valuated quite expensively with a Price/Earnings ratio of 30.17.
Based on the Price/Earnings ratio, GLUE is valued cheaper than 93.28% of the companies in the same industry.
When comparing the Price/Earnings ratio of GLUE to the average of the S&P500 Index (27.53), we can say GLUE is valued inline with the index average.
The Forward Price/Earnings Ratio is negative for GLUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 30.17
Fwd PE N/A
GLUE Price Earnings VS Forward Price EarningsGLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GLUE is valued cheaply inside the industry as 97.57% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GLUE indicates a rather cheap valuation: GLUE is cheaper than 94.40% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 27.34
EV/EBITDA 7.49
GLUE Per share dataGLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as GLUE's earnings are expected to decrease with -7.56% in the coming years.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y-16.8%
EPS Next 3Y-7.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (10/16/2025, 1:11:18 PM)

10.56

-0.55 (-4.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners100.28%
Inst Owner Change-0.02%
Ins Owners0.85%
Ins Owner Change-0.02%
Market Cap652.19M
Analysts84
Price Target17.05 (61.46%)
Short Float %13.46%
Short Ratio6.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)162.39%
Min EPS beat(2)61.87%
Max EPS beat(2)262.91%
EPS beat(4)4
Avg EPS beat(4)361.68%
Min EPS beat(4)41.55%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)176.66%
EPS beat(12)11
Avg EPS beat(12)118.84%
EPS beat(16)13
Avg EPS beat(16)84.29%
Revenue beat(2)2
Avg Revenue beat(2)277.73%
Min Revenue beat(2)110.55%
Max Revenue beat(2)444.91%
Revenue beat(4)4
Avg Revenue beat(4)305.64%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.63%
PT rev (3m)2.63%
EPS NQ rev (1m)-9.44%
EPS NQ rev (3m)6.74%
EPS NY rev (1m)9.21%
EPS NY rev (3m)65.71%
Revenue NQ rev (1m)-34.85%
Revenue NQ rev (3m)-40.26%
Revenue NY rev (1m)-3.33%
Revenue NY rev (3m)19.2%
Valuation
Industry RankSector Rank
PE 30.17
Fwd PE N/A
P/S 3.66
P/FCF 27.34
P/OCF 23.53
P/B 2.43
P/tB 2.43
EV/EBITDA 7.49
EPS(TTM)0.35
EY3.31%
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)0.39
FCFY3.66%
OCF(TTM)0.45
OCFY4.25%
SpS2.88
BVpS4.34
TBVpS4.34
PEG (NY)0.37
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.72%
ROE 9.02%
ROCE 4.71%
ROIC 3.72%
ROICexc 43.54%
ROICexgc 43.54%
OM 8.4%
PM (TTM) 13.58%
GM N/A
FCFM 13.4%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 46.35%
Cap/Sales 2.17%
Interest Coverage 250
Cash Conversion 118.97%
Profit Quality 98.69%
Current Ratio 7.16
Quick Ratio 7.16
Altman-Z 4.42
F-Score8
WACC9.36%
ROIC/WACC0.4
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
EPS Next Y80.7%
EPS Next 2Y-16.8%
EPS Next 3Y-7.56%
EPS Next 5Y-6.65%
Revenue 1Y (TTM)2990.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%394.01%
Revenue Next Year413.34%
Revenue Next 2Y39.97%
Revenue Next 3Y36.05%
Revenue Next 5Y22.64%
EBIT growth 1Y110.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.33%
EBIT Next 3Y21.23%
EBIT Next 5YN/A
FCF growth 1Y120.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.71%
OCF growth 3YN/A
OCF growth 5YN/A